Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
StrataGraft in full-thickness complex skin defects
NCT03005054Phase 2Terminated
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Apr 2017
- Primary completion
- Mar 2019
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen, sponsored by Mallinckrodt Pharmaceuticals. Primary endpoints: Percent Area of the StrataGraft Treatment Site Requiring Autografting by Three Months at 3 months and Percentage of Participants With Complete Wound Closure of the Treatment Sites at Three Months at 3 months. Started Apr 2017; status: terminated.
02
Drugs
allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen
Beyond the preview
Go deeper on NCT03005054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03005054.